MEDI-563 ( DrugBank: - )


5 diseases
IDDisease name (Link within this page)Number of trials
44Wegener granulomatosis4
45Eosinophilic granulomatosis with Polyangiitis4
98Eosinophilic gastrointestinal disease7
162Pemphigoid5
299Cystic fibrosis3

44. Wegener granulomatosis


Clinical trials : 98Drugs : 108 - (DrugBank : 28) / Drug target genes : 22 - Drug target pathways : 81 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

45. Eosinophilic granulomatosis with Polyangiitis


Clinical trials : 31Drugs : 44 - (DrugBank : 18) / Drug target genes : 18 - Drug target pathways : 101 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

98. Eosinophilic gastrointestinal disease


Clinical trials : 172Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

162. Pemphigoid


Clinical trials : 90Drugs : 122 - (DrugBank : 47) / Drug target genes : 34 - Drug target pathways : 144 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

299. Cystic fibrosis


Clinical trials : 1,695Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries